Early Use of Corticosteroids following CAR T-Cell Therapy Correlates with Reduced Risk of High-Grade CRS without Negative Impact on Neurotoxicity or Treatment Outcome

Early Use of Corticosteroids following CAR T-Cell Therapy Correlates with Reduced Risk of High-Grade CRS without Negative Impact on Neurotoxicity or Treatment Outcome

Background: Chimeric antigen receptor T-cell therapy (CAR T-cell therapy) is associated with potentially life-threatening toxicities, most commonly cytokine release syndrome (CRS) and immune-effector-cell-associated neurotoxicity syndrome (ICANS). These frequent adverse events are managed with the I...

Full description

Bibliographic Details
Main Authors: Tim Lakomy, Dilara Akhoundova, Henning Nilius, Marie-Noëlle Kronig, Urban Novak, Michael Daskalakis, Ulrike Bacher, Thomas Pabst
Format: Article
Language:English
Published: MDPI AG 2023-02-01
Series:Biomolecules
Subjects:
CAR T-cell therapy
adverse events
CRS
neurotoxicity
ICANS
tocilizumab
Online Access:https://www.mdpi.com/2218-273X/13/2/382

Internet

https://www.mdpi.com/2218-273X/13/2/382

Similar Items